PRESS-RELEASE ·Filed Jun 9, 2026
Press release · FDA
Actionable Insight • Neutral
Monitor for interim or top-line data from PREDICT-1, which could serve as a significant catalyst.
Final — all horizons settled through T+60d
OCS ▲ +9.47% at T+60d
NEUTRAL call +9.47% · α vs SPY +5.66% · entry $10.98 → $12.02
T+1d
-0.09%
call -0.09% · α +1.49%
$10.97
settled 5mo ago
T+5d
+5.74%
call +5.74% · α +3.33%
$11.61
settled 4mo ago
T+20d
+23.50%
call +23.50% · α +22.05%
$13.56
settled 4mo ago
T+60d
+9.47%
call +9.47% · α +5.66%
$12.02
settled 8w ago
Price Chart
Loading chart...
Executive Summary
Oculis announced the first patient randomized in PREDICT-1, a genotype-based registrational trial for Licaminlimab in dry eye disease. This is a key milestone for a first-in-class precision medicine approach targeting TNFR1 genotype patients, but the trial is early-stage with no efficacy data yet.
Key Facts
- First patient randomized in PREDICT-1, a registrational trial for Licaminlimab in dry eye disease (DED).
- Trial plans to enroll ~160 patients, with ~2/3 having a specific TNFR1 genotype.
- Primary endpoint: change from baseline to Day 29 in global ocular discomfort severity score in TNFR1 genotype patients.
- Phase 2 data showed 5- to 7-fold more pronounced treatment effect in patients with TNFR1 variant.
- Only 13% of DED patients experience sustained relief with current treatments; 85-90% discontinue within 6 months.
- Licaminlimab is an investigational drug with no regulatory approval for commercial use.
Financial Impact
No financial data disclosed; trial is early-stage with no revenue impact expected for years.
Risk Factors
- Clinical trial failure: PREDICT-1 may not meet primary endpoint.
- Regulatory risk: Licaminlimab has not received approval for any indication.
- Competition: DED market has existing therapies and other pipeline candidates.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308587 |
13 reports for OCS
75% Hit rate @ T+5 Went positive at some point 4 of 4 best @ T+5▲ +50.63%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 6-K | $8.76 $8.66 | ▼ −1.14% | ▼ −2.44% | $7.83 (−10.62%) |
Aug 10, 2026 11w ago | 6-K | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $7.83 (−38.64%) |
Aug 10, 2026 11w ago | Press Release | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $7.83 (−38.64%) |
Jun 11, 2026 19w ago | Press Release | $11.00 $11.30 | ▲ +2.73% | ▲ +2.29% | $7.83 (−28.82%) |
Jun 9, 2026 20w ago | Press Release | $10.98 $11.61 | ▲ +5.74% | ▲ +3.33% | $7.83 (−28.69%) |
May 29, 2026 21w ago | Press Release | $22.71 $11.21 | ▲ +50.63% | ▲ +48.10% | $7.83 (+65.51%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $7.83 (−74.25%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $7.83 (−74.25%) |
May 7, 2026 24w ago | Press Release | $31.09 $31.37 | ▲ +0.90% | ▼ −0.60% | $7.83 (−74.82%) |
May 5, 2026 25w ago | Press Release | $27.75 $30.41 | ▲ +9.59% | ▲ +7.60% | $7.83 (−71.78%) |
Showing 10 of 13
US Market Status
Market Closed — Opens Wed (15h 33m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers